: Estimated treatment differences for change from baseline to end of treatment in the six individual DTSQ questions contributing to overall treatment satisfaction *p<0.05 for comparison between semaglutide and comparators/placebo. Data are presented as ETD [95% CI]. Mean observed values are based on the FAS and LOCF imputed data. For SUSTAIN 2-5, post-baseline data were analysed using an ANCOVA model with treatment, country and stratum as fixed factors and baseline value as covariate. Mean estimates were adjusted according to observed baseline distribution. For SUSTAIN 7, post-baseline data were analysed using an MMRM with treatment and country as fixed factors and baseline value as covariate, all nested within visit. In SUSTAIN 7, semaglutide 0.5 mg was compared with dulaglutide 0.75 mg and semaglutide 1.0 mg with dulaglutide 1.5 mg. ANCOVA, analysis of covariance; CI, confidence interval; DTSQ, Diabetes Treatment Satisfaction Questionnaire; ETD, estimated treatment difference; exenatide ER, exenatide extended release; FAS, full analysis set; IGlar, insulin glargine; LOCF, last observation carried forward; MMRM, mixed model for repeated measurements.
